

Jeongwu Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5254522/publications.pdf>

Version: 2024-02-01

31
papers

5,675
citations

236925

25
h-index

454955

30
g-index

32
all docs

32
docs citations

32
times ranked

9712
citing authors

#	ARTICLE	IF	CITATIONS
1	Modulation of Nogo receptor 1 expression orchestrates myelin-associated infiltration of glioblastoma. <i>Brain</i> , 2021, 144, 636-654.	7.6	16
2	Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. <i>Genome Biology</i> , 2020, 21, 216.	8.8	73
3	ARS2/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages. <i>Nature Communications</i> , 2020, 11, 2978.	12.8	78
4	PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma. <i>Journal of Experimental Medicine</i> , 2019, 216, 1120-1134.	8.5	27
5	Secretome analysis of patient-derived GBM tumor spheres identifies midkine as a potent therapeutic target. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-11.	7.7	28
6	Statins affect human glioblastoma and other cancers through TGF- β 2 inhibition. <i>Oncotarget</i> , 2019, 10, 1716-1728.	1.8	30
7	Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. <i>Neuro-Oncology</i> , 2018, 20, 192-202.	1.2	52
8	CADD-57. THE EFFICACY OF THERAPY WITH ABT-414, AN EGFR-TARGETING ADC, IS POTENTIALLY ALTERED BY HETEROZYGOUS DELETION OF THE ENDOCYTIC TRAFFICKING REGULATOR RBSN. <i>Neuro-Oncology</i> , 2018, 20, vi283-vi284.	1.2	0
9	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. <i>Nature Genetics</i> , 2018, 50, 1399-1411.	21.4	145
10	Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. <i>Cancer Research</i> , 2018, 78, 4360-4369.	0.9	46
11	Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth. <i>Cancer Research and Treatment</i> , 2018, 50, 1009-1022.	3.0	21
12	Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBP β Signaling. <i>Cancer Research</i> , 2017, 77, 4973-4984.	0.9	68
13	Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms. <i>Clinical Cancer Research</i> , 2017, 23, 6958-6968.	7.0	74
14	CDK4/6 inhibition is more active against the glioblastoma proneural subtype. <i>Oncotarget</i> , 2017, 8, 55319-55331.	1.8	39
15	MET: roles in epithelial-mesenchymal transition and cancer stemness. <i>Annals of Translational Medicine</i> , 2017, 5, 5-5.	1.7	69
16	Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges. <i>Oncology Letters</i> , 2016, 11, 1281-1286.	1.8	50
17	WNT signaling in glioblastoma and therapeutic opportunities. <i>Laboratory Investigation</i> , 2016, 96, 137-150.	3.7	200
18	FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2. <i>PLoS ONE</i> , 2015, 10, e0137703.	2.5	89

#	ARTICLE	IF	CITATIONS
19	Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. <i>Cell Reports</i> , 2015, 13, 2425-2439.	6.4	146
20	EZH2 Protects Glioma Stem Cells from Radiation-Induced Cell Death in a MELK/FOXM1-Dependent Manner. <i>Stem Cell Reports</i> , 2015, 4, 226-238.	4.8	159
21	Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII Promotes Self-renewal and Tumor Progression of Glioma Stem Cells. <i>PLoS Biology</i> , 2015, 13, e1002152.	5.6	56
22	Spatiotemporal Evolution of the Primary Glioblastoma Genome. <i>Cancer Cell</i> , 2015, 28, 318-328.	16.8	242
23	<i>In vivo</i> RNAi screen identifies NLK as a negative regulator of mesenchymal activity in glioblastoma. <i>Oncotarget</i> , 2015, 6, 20145-20159.	1.8	23
24	Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme. <i>Oncotarget</i> , 2015, 6, 27239-27251.	1.8	23
25	Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling. <i>OncoTargets and Therapy</i> , 2014, 7, 1933.	2.0	53
26	Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells. <i>Cancer Cell</i> , 2013, 23, 839-852.	16.8	665
27	SSEA-1 Is an Enrichment Marker for Tumor-Initiating Cells in Human Glioblastoma. <i>Cell Stem Cell</i> , 2009, 4, 440-452.	11.1	598
28	Epigenetic-Mediated Dysfunction of the Bone Morphogenetic Protein Pathway Inhibits Differentiation of Glioblastoma-Initiating Cells. <i>Cancer Cell</i> , 2008, 13, 69-80.	16.8	415
29	Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. <i>Cancer Cell</i> , 2006, 9, 391-403.	16.8	2,056
30	Cellular and genetic characterization of human adult bone marrow-derived neural stem-like cells: a potential antiglioma cellular vector. <i>Cancer Research</i> , 2003, 63, 8877-89.	0.9	69
31	Antitumor Activity and Prolonged Expression from a TRAIL-Expressing Adenoviral Vector. <i>Neoplasia</i> , 2002, 4, 312-323.	5.3	65